Answers are grounded in this paper and cite their sources.
Candida albicans infections are a substantial cause of illness burden in immunocompromised patients.The opportunistic pathogen, C. albicans is polymorphic in nature which shows commensalism in humans, and colonizes mostly mucosal surfaces of the human body, including the respiratory, urinary, genital, gastrointestinal tracts and oropharyngeal cavity.It can cause infections which range from superficial infections such as oral thrush to serious infections like candidemia and disseminated candidiasis.These infections occur when Candida spp.undergo a reversible morphological transition from yeast to filamentous form.Significant efforts are focused on the mechanisms that control this transition.Antifungal drugs such as azoles, polyenes, allylamines and echinocandins are most commonly used in the treatment of Candida infected patients.The toxicity of antifungal medications on human cells, coupled with the increasing resistance of Candida infections to these drugs, highlights the necessity for the development of novel strategies to enhance the well-being of patients affected by such infections.Lactobacillus spp.found in the human microbiome are the natural competitors of Candida spp.and have the potential to control fungal growth.Lactic acid bacteria are cocci or rod-shaped, Gram-positive, non-spore forming bacteria.LAB produces lactic acid and other metabolites which suppress filamentation, a key virulence feature of C. albicans.This review provides a comprehensive overview of novel strategies in the prevention of Candida infections by highlighting the significance of LAB.
No takes yet. Share an insight, caveat, or question.
Vikrant et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: